Tagged News

Novo Nordisk CEO Steps Down After Eight Years as Company Faces Market Pressures

3 months ago

Novo Nordisk CEO Lars Fruergaard Jørgensen announced his resignation after eight years leading the company through significant growth in the obesity treatment market.
The departure follows mounting competitive pressures and a notable decline in share price since mid-2024, prompting the Novo Nordisk Foundation board to seek leadership succession.
Former CEO Lars Rebien Sørensen will join the board as an observer while the company conducts a search for Jørgensen's permanent replacement.
Jørgensen will remain in his role temporarily to ensure a smooth transition during this critical period for the Danish pharmaceutical giant.

4 months ago

Dr. Nicholas Botwood joins Syndax Pharmaceuticals from Bristol Myers Squibb, bringing 25 years of oncology drug development and commercialization experience to accelerate the company's cancer therapy pipeline.
The appointment comes as Syndax continues to expand its portfolio, which includes FDA-approved Revuforj (menin inhibitor) and Niktimvo (axatilimab-csfr), a monoclonal antibody targeting the CSF-1 receptor.
Dr. Botwood succeeds Dr. Neil Gallagher, who oversaw multiple positive data readouts, two product approvals, and the recent submission of Revuforj's supplemental New Drug Application for relapsed or refractory mNPM1 acute myeloid leukemia.

4 months ago

Orca Bio has appointed co-founder and Chief Scientific Officer Nate Fernhoff, Ph.D., as Chief Executive Officer, succeeding Ivan Dimov, Ph.D.
Co-founder Jeroen Bekaert, Ph.D., has been promoted from Chief Operating Officer to President to oversee operations across all organizational areas.
The leadership changes come as the company prepares for a planned 2025 BLA submission to the FDA for Orca-T following positive Phase 3 results.
Orca Bio is accelerating investments in manufacturing infrastructure and commercial operations to support the potential launch of its allogeneic T-cell immunotherapy.

5 months ago

Werner Cautreels, PhD, is retiring as CEO of Traws Pharma effective March 31, 2025, while continuing as a Board Member and special advisor for the next year.
Executive Board Chairman Iain D. Dukes, D Phil, will step in as Interim CEO while maintaining his role as Chairman of the clinical-stage biopharmaceutical company.
Under Cautreels' leadership, Traws Pharma completed a merger with Trawsfynydd and advanced two clinical-stage antiviral candidates targeting bird flu and COVID.

5 months ago

EKF Diagnostics Holdings plc has appointed Gavin Jones as Chief Executive Officer with immediate effect, promoting him from his previous role as Chief Product Officer.
Jones brings over twenty years of experience in point-of-care and life sciences, having led product management, R&D, marketing and regulatory departments at EKF since 2013.
The company reported revenues of £50.2m for 2024 with adjusted EBITDA climbing 9.2% to £11.3m, reflecting a strategic shift toward higher-margin products and services.
Founder Julian Baines will remain as Executive Chair and emphasized Jones' ambitious plans for delivering sustainable growth and unlocking unrealized potential in core products.